https://img1.wsimg.com/isteam/videos/udeAdbLlgMiVYokPL

7th ANNUAL EMERGING FRONTIERS IN ONCOLOGY

May 22, 2025 | 1:00PM - 8:00 PM ET

MassBio Hub | 700 Tech Square 5th floor, Cambridge, MA

Reception | Catalyst Restaurant

7th ANNUAL EMERGING FRONTIERS IN ONCOLOGY

May 22, 2025 | 1:00PM - 8:00 PM ET

MassBio Hub | 700 Tech Square 5th floor, Cambridge, MA

Reception | Catalyst Restaurant

Investing in Oncology

Aligning Stakeholders Amid Shifting Perspectives

Our 2025 theme will explore the evolving dynamics of oncology investment, analyzing perspectives from key stakeholders—foundations, investors, biopharma, entrepreneurs, and researchers. Through this lens, we will provide a forward-looking view on emerging opportunities in a rapidly shifting market.

Research: What's likely to shape the future innovation funnel?
Innovation: What is the optimal investment approach for 2025? Should stakeholders adopt a "watch and wait" approach or make strategic bets?
People: Who are the key players, and how can their unique skills create lasting value?

This off-the-record summit aims to facilitate broad and open discussions, encouraging diverse viewpoints and meaningful exchanges. Join us as we navigate these critical conversations and chart a unified path forward for oncology investment in 2025.

Event Details

1:00 p.m. | Registration

1:30 p.m. | Welcome Remarks

Uciane Scarlett, Host

1:40 p.m. | Research: What’s likely to shape the innovation funnel

(fire-side chat – 40 mins)

John Connolly, PhD - CSO, Parker Institute for Cancer Immunotherapy (PICI)

Moderator: Uciane Scarlett, PhD - former principal, MPM BioImpact

2:20 p.m. | Innovation Bridge: Oncology Bull and Bear Cases

Ricardo Brau, PhD - Managing Director & Partner, L.E.K.

Lain Anderson - Managing Director & Co-Head of Americas Healthcare Sector, L.E.K.

2:50 p.m. | Innovation: Optimal approach for 2025 - watch & wait vs strategic bets

(debate-style panel – 60 mins)

Alexis Borisy - Operating Chairman, Curie.Bio

Irina Margine, PhD - Biotech Sector Lead, Wellington Management

Jean-François Formela, MD - Partner, Atlas Ventures

Keith Flaherty, MD - Professor, MGH; Co-founder Loxo Oncology, Scorpion Therapeutics

Errik Anderson - CEO, Alloy Tx, GP, 82VS

Joe Pearlberg, MD, PhD - VP of Scientific Affairs, Deerfield Management

Moderator: Prashant Girinath, PhD- Shareholder, Greenberg Traurig

3:50 p.m. | People: Stakeholders and their value cycles

(round table – 60 mins)

Micah Benson, PhD - CSO, KSQ

Paulina Hill, PhD – Partner, Sanofi Ventures

Colin Hill, M.S - CEO, Co-founder, Aitia Bio

Stephanie Oestreich, PhD, MPA - Managing Director, Myeloma Investment Fund

Tim Clackson, PhD - CEO, IDRx

Moderator: Luba Greenwood, J.D. - CEO, Gallop Onc, EiR PureTech

4:50 p.m. | Closing Remarks

Yung Lie, PhD - President & CEO, Damon Runyon

John Connolly, PhD - CSO, Parker Institute for Cancer Immunotherapy, PICI

5:00-8:00 p.m. | Greenberg Traurig hosted Reception at Catalyst